Clinical efficacy and safety of edaravone combined with butylphthalide in treatment of acute cerebral ischemic stroke
10.13699/j.cnki.1001-6821.2015.16.003
- VernacularTitle:依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效及安全性评价
- Author:
Xing-Le GAO
1
;
Li-Yu CHEN
;
Le-Qiu SUN
;
Xiao-Rong LI
;
Guo-Qing ZHENG
Author Information
1. 温州医科大学 附属乐清医院 神经内科
- Keywords:
acute cerebral ischemic stroke;
edaravone;
butylphthalide;
clinical efficacy;
neurological function
- From:
The Chinese Journal of Clinical Pharmacology
2015;(16):1569-1571
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of edaravone combined with butylphthalide in treatment of acute cerebral ischemic stroke.Methods Eighty-three patients with acute cerebral ischemic stroke in the department of neurology of the Leqing People′s Hospital. And the included 83 cases were randomly divided into treatment group ( n =40 ) and control group ( n =43 ) . All of the included patients were underwent treatment of anti -platelet and depressurization.Patients in the control group were also treated with edaravone 30 mg+0.9%sodium chloride 100 mL intravenous transfusion bid ×14 d. And patients in the treatment group were administered butylphthalide 200 mg po, tid ×14 d. After treatment, the clinical efficacy and neurological function between the two groups were evaluated. Results The total clinical efficacy was not statistical significant (82.50% vs 76.74%) between the two groups ( P>0.05) , but the treatment group had the trend of higher compared to control group.The neurological score of the two groups were all improved significantly (P<0.05).And the treatment group was superior to control group (P<0.05).The adverse incidence rate were 10.00% and 4.65% in the treatment and control group respectively with no statistical different (P>0.05).ConclusionEdaravonecombinedwithbutylphthalideintreatmentofacutecerebralischemicwas effective and safe.
